Head to head
VK2735 against Tirzepatide
The same pair of receptors, GLP-1 and GIP, in an approved drug and in a phase 3 candidate. Anyone weighing these two is weighing a finished evidence package against an unfinished one.
Column A
VK2735VK2735 (dual GLP-1 / GIP agonist)
Viking Therapeutics' dual GLP-1 and GIP agonist in Phase 3 as an injection, with an oral version showing rapid early weight loss.
Column B
TirzepatideTirzepatide (dual GIP/GLP-1 receptor agonist)
A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists.
Side by side, on the facts we can check
| Attribute | VK2735 | Tirzepatide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational (Phase 3 VANQUISH-1 and VANQUISH-2 fully enrolled; oral form completed Phase 2) | FDA-approved (Mounjaro for T2D and, from August 2026, to reduce major cardiovascular events in T2D; Zepbound for weight management and sleep apnea) |
| Half-life | Supports weekly dosing (injectable) | ~5 days |
| Molecular weight | Not disclosed | 4,813.5 Da |
| Mechanism | Agonizes both the GLP-1 and GIP receptors to enhance insulin secretion, reduce appetite, and slow gastric emptying. | Simultaneously activates GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, reducing glucagon, delaying gastric emptying, and reducing appetite. The GIP component is thought to add complementary metabolic effects. |
| Human studies cited | 3 | 4 |
| Legal status, US | Investigational, not approved | FDA-approved, prescription only |
Frequently asked questions
What is the difference between VK2735 and Tirzepatide?
VK2735: Viking Therapeutics' dual GLP-1 and GIP agonist in Phase 3 as an injection, with an oral version showing rapid early weight loss. Tirzepatide: A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists.
Which has stronger research evidence, VK2735 or Tirzepatide?
This database does not grade compounds. It counts what was run in people: 3 of the 3 studies cited on the VK2735 profile were human work, against 4 of 4 for Tirzepatide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are VK2735 and Tirzepatide FDA-approved?
VK2735: Investigational (Phase 3 VANQUISH-1 and VANQUISH-2 fully enrolled; oral form completed Phase 2). Tirzepatide: FDA-approved (Mounjaro for T2D and, from August 2026, to reduce major cardiovascular events in T2D; Zepbound for weight management and sleep apnea).
Related posts
Blog articles that cover VK2735 or Tirzepatide, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
- Metabolic / Sep 8, 2026 / 9 minMariTide (Maridebart Cafraglutide): The Once-Monthly GLP-1 Agonist and GIP Blocker, Explained
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.